KRAS and neoplasm: Since the majority of the cases were routine small biopsies, and a panel of IHC markers initially diagnosed the cases, then were further evaluated for molecular alterations, namely EGFR, KRAS, ALK, and PD-L1, no more biological material with tumor content was available for molecular validation in half of the pan-TRK-positive cases.